Leap Therapeutics is laying off half of its staff as the company narrows the focus of its lead cancer drug against the ...

Azafaros has secured 132 million euros ($147 million) in series B funds that the Dutch biotech will use to push its rare ...

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...

An appeals court has opened another chapter in the long-running CRISPR patent saga. | An appeals court has opened another ...

CapsoVision has filed to go public, with plans to raise up to $30 million to support the development of its swallowable ...

The uncertainty around splitting up the business is only the latest in a series of strategic shake-ups at Galapagos in recent years. Other major events have included the pivot to CAR-Ts in 2022 and ...

The founder and former leader of Inhibikase Therapeutics is blazing a new biotech trail in an effort to get a beleaguered ...

North Carolina-based CRO Fortrea is saying goodbye to its CEO. | North Carolina-based CRO Fortrea is saying goodbye to its ...

California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of ...

Biotech bank balances were again in focus Monday morning, with Tango Therapeutics cutting preclinical work to stretch its ...

Lexeo Therapeutics laid off 15% of its staff last month as part of a wider plan to siphon $20 million from its wider pipeline ...

Dynavax’s battle with activist investor Deep Track Capital over the biopharma’s direction has heated up again as the ...